Spotlight on Peginterferon-α-2a (40KD) in Chronic Hepatitis C

被引:0
作者
Caroline M. Perry
Blair Jarvis
机构
[1] Adis International Limited,
[2] 41 Centorian Drive,undefined
来源
BioDrugs | 2002年 / 16卷
关键词
Chronic Hepatitis; Sustained Virological Response; Virological Response; Fatigue Severity Scale; Histological Improvement;
D O I
暂无
中图分类号
学科分类号
摘要
Peginterferon-α-2a (40KD) is a new ‘pegylated’ subcutaneous formulation of interferon-α-2a that has been developed to improve on the pharmacokinetic profile and therapeutic efficacy of interferon-α-2a. Peginterferon-α-2a (40KD) is produced by the covalent attachment of recombinant interferon-α-2a to a branched mobile 40KD polyethylene glycol moiety, which shields the interferon-α-2a molecule from enzymatic degradation, reduces systemic clearance and enables once-weekly administration.
引用
收藏
页码:213 / 217
页数:4
相关论文
共 50 条
  • [23] Meloxicam as an adjuvant to peginterferon-α-2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial
    Kagawa, Tatehiro
    Kojima, Sei-ichiro
    Shiraishi, Koichi
    Hirose, Shunji
    Arase, Yoshitaka
    Takashimizu, Shinji
    Watanabe, Norihito
    Nagata, Naruhiko
    Numata, Makoto
    Shiozawa, Hirokazu
    Nishizaki, Yasuhiro
    Toki, Mayu
    Sugita, Teruji
    Nomura, Kijuro
    Sakaguchi, Takashi
    Atsukawa, Kazuhiro
    Tajima, Hiroto
    Tei, Yoshihiro
    Inomoto, Tsutomu
    Mine, Tetsuya
    [J]. HEPATOLOGY RESEARCH, 2013, 43 (09) : 925 - 932
  • [26] Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
    Nelson, David R.
    Zeuzem, Stefan
    Andreone, Pietro
    Ferenci, Peter
    Herring, Robert
    Jensen, Donald M.
    Marcellin, Patrick
    Pockros, Paul J.
    Rodriguez-Torres, Maribel
    Rossaro, Lorenzo
    Rustgi, Vinod K.
    Sepe, Thomas
    Sulkowski, Mark
    Thomason, Isaac R.
    Yoshida, Eric M.
    Chan, Anna
    Hill, George
    [J]. ANNALS OF HEPATOLOGY, 2012, 11 (01) : 15 - 31
  • [27] Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis
    Bruno, Savino
    Shiffman, Mitchell L.
    Roberts, Stuart K.
    Gane, Edward J.
    Messinger, Diethelm
    Hadziyannis, Stephanos J.
    Marcellin, Patrick
    [J]. HEPATOLOGY, 2010, 51 (02) : 388 - 397
  • [29] Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon α-2a (40KD) plus ribavirin
    Snoeck, Eric
    Hadziyannis, Stephanos J.
    Puoti, Claudio
    Swain, Mark G.
    Berg, Thomas
    Marcellin, Patrick
    Zarski, Jean-Pierre
    Jorga, Karin
    Zeuzem, Stefan
    [J]. LIVER INTERNATIONAL, 2008, 28 (01) : 61 - 71